March 2015

Sustained virological response after only 5 weeks treatment with daclatasvir/pegylated interferon and ribavirin as part of a clinical trial in a cirrhotic human immunodeficiency virus (HIV) - hepatitis C virus (HCV) co-infected patient with liver decompensation during treatment

This study presents a case of a sustained virological response to 24 weeks early cessation of hepatitis C direct acting antiviral (DAA) treatment with daclatasvir/peginterferon (PEG-IFN)/ribavirin (RBV), mandated by liver decompensation, in a clinical trial subject with advanced liver disease and human immunodeficiency virus (HIV)/hepatitis C virus (HCV) co-infection. Key words: Human immunodeficiency virus (HIV),...

Author(s): S. Flanagan, A. Umaipalan, G. Baily and C. Orkin